305 related articles for article (PubMed ID: 31613663)
1. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
[No Abstract] [Full Text] [Related]
2. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma.
Oldrini G; Huertas A; Renard-Oldrini S; Taste-George H; Vogin G; Laurent V; Salleron J; Henrot P
PLoS One; 2017; 12(4):e0176118. PubMed ID: 28441447
[TBL] [Abstract][Full Text] [Related]
3. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
4. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.
Mendiratta-Lala M; Masch W; Shankar PR; Hartman HE; Davenport MS; Schipper MJ; Maurino C; Cuneo KC; Lawrence TS; Owen D
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):169-179. PubMed ID: 30213751
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
[TBL] [Abstract][Full Text] [Related]
7. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.
Price TR; Perkins SM; Sandrasegaran K; Henderson MA; Maluccio MA; Zook JE; Tector AJ; Vianna RM; Johnstone PA; Cardenes HR
Cancer; 2012 Jun; 118(12):3191-8. PubMed ID: 22025126
[TBL] [Abstract][Full Text] [Related]
10. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis.
Sanuki N; Takeda A; Mizuno T; Oku Y; Eriguchi T; Iwabuchi S; Kunieda E
AJR Am J Roentgenol; 2013 Dec; 201(6):W812-20. PubMed ID: 24261388
[TBL] [Abstract][Full Text] [Related]
11. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled Trial.
Lee VH; Vardhanabhuti V; Wong TC; Lam KO; Choi HC; Chiu KW; Ho PP; Leung DK; Szeto MH; Choi KF; Chan SC; Leung TW; Khong PL; Lo CM
JAMA Netw Open; 2024 Jun; 7(6):e2415998. PubMed ID: 38857045
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
Moore A; Cohen-Naftaly M; Tobar A; Kundel Y; Benjaminov O; Braun M; Issachar A; Mor E; Sarfaty M; Bragilovski D; Hur RB; Gordon N; Stemmer SM; Allen AM
Radiat Oncol; 2017 Oct; 12(1):163. PubMed ID: 29052532
[TBL] [Abstract][Full Text] [Related]
14. Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation.
Mastrocostas K; Fischer S; Munoz-Schuffenegger P; Jang HJ; Dawson LA; Liu ZA; Sapisochin G; Kim TK
Abdom Radiol (NY); 2021 Apr; 46(4):1572-1585. PubMed ID: 33074426
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience.
Wigg AJ; Narayana SK; Le H; Iankov I; Chinnaratha MA; Tse E; Chen JW; Gowda R
ANZ J Surg; 2019 Sep; 89(9):1138-1143. PubMed ID: 30983104
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Lewis S; Cedillo MA; Lee KM; Bane O; Hectors S; Ma W; Wang P; Stocker D; Morris DV; Pinato D; Sung M; Marron T; Schwartz M; Taouli B
Abdom Radiol (NY); 2022 Mar; 47(3):969-980. PubMed ID: 34964909
[TBL] [Abstract][Full Text] [Related]
18. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
[No Abstract] [Full Text] [Related]
19. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial.
Yoon SM; Kim SY; Lim YS; Kim KM; Shim JH; Lee D; An J; Jung J; Kim JH; Lee HC
Clin Mol Hepatol; 2020 Oct; 26(4):506-515. PubMed ID: 32646200
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
